IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) will be participating in a fireside chat at the 2024 RBCCM Global Healthcare Conference on May 14, 2024. The event will be webcasted live and available for replay on the company's website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – IGMS
In the trading session that priced this news, IGMS declined 1.00%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies against immunology and inflammation targets. For more information, please visit www.igmbio.com.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
